Transient Ischemic Attack

Clinical Trial Finder

Many patients who experience transient ischemic attacks (TIAs) are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Pilot Study of Acute Stroke Using the Brainpulse™

Condition:   Stroke, Acute
Intervention:   Device: BrainPulse Device
Sponsor:   Jan Medical, Inc.
Not yet recruiting - verified August 2017

The Recurrence Study

Conditions:   Acute Stroke;   Transient Ischemic Attack
Interventions:   Diagnostic Test: Corneal Confocal Imaging;   Diagnostic Test: Magnetic resonance Imaging;   Other: Blood sample
Sponsor:   Hamad Medical Corporation
Recruiting - verified August 2017

SpecTRA; A Study of the Validation of Protein Biomarkers in Transient Ischemic Attack

Condition:   TIA
Intervention:   Other: Non-Interventional Study
Sponsors:   Andrew Penn;   Genome Canada;   Genome British Columbia;   Genome Alberta;   Vancouver Island Health Authority;   LifeLabs;   Heart and Stroke Foundation of Canada;   Stroke Services BC;   Bruker Daltonics;   British Columbia Centre for Disease Control
Completed - verified August 2017

Carotid Atherosclerosis : Innovative Imaging Biomarkers. Study Case-control

Condition:   Carotid Stenosis
Intervention:   Device: HITS quantification, Ultrasound examinations, High Resolution MRI
Sponsors:   Hospices Civils de Lyon;   Fondation de France;   Bracco Imaging S.p.A.
Recruiting - verified August 2017

A Study of the ReCor Medical Paradise System in Clinical Hypertension

Conditions:   Hypertension;   Vascular Diseases
Interventions:   Device: The Paradise® Renal Denervation Ultrasound System;   Device: Sham Procedure
Sponsor:   ReCor Medical, Inc.
Recruiting - verified May 2017

Study of the Performance of Stroke Management in the Rhône Area

Condition:   Stroke
Sponsor:   Hospices Civils de Lyon
Recruiting - verified August 2017

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified August 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified August 2017

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Condition:   Stroke
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
Sponsors:   Bayer;   Janssen, LP;   Hamilton Health Sciences Cooperation, Population Health Research Institute
Recruiting - verified August 2017

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2017

Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)

Conditions:   Ischemic Stroke;   Atrial Fibrillation;   Transient Ischemic Attacks;   Transient Cerebrovascular Events;   Thrombotic Stroke;   Stroke of Basilar Artery;   Cardioembolic Stroke
Intervention:   Other: Biomarker blood draw
Sponsor:   Ischemia Care LLC
Recruiting - verified August 2017

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2017

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Condition:   Ischemic Attack, Transient
Interventions:   Drug: Clopidogrel;   Drug: placebo
Sponsors:   University of California, San Francisco;   Neurological Emergencies Treatment Trials Network (NETT);   Medical University of South Carolina;   The EMMES Corporation
Recruiting - verified August 2017

GORE® HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder for Patent Foramen Ovale (PFO) Closure in Stroke Patients - The Gore REDUCE Clinical Study

Conditions:   Stroke;   Transient Ischemic Attack
Interventions:   Device: GORE® HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder;   Other: Antiplatelet Medical Therapy
Sponsor:   W.L.Gore & Associates
Active, not recruiting - verified August 2017